Alzheimer's disease (AD) progression is highly heterogeneous and is typically observed through sparse and irregular longitudinal data, posing challenges for prediction and personalised monitoring. Existing machine learning approaches have improved AD prediction using multimodal data, yet often focus on static classification or cohort-level risk estimation, providing limited support for subject-specific modelling and uncertainty-aware reasoning.
arXiv:2606. 09671v1 Announce Type: cross Abstract: Alzheimer's disease (AD) progression is highly heterogeneous and is typically observed through sparse and irregular longitudinal data, posing challenges for prediction and personalised monitoring.
arXiv:2606. 24604v1 Announce Type: new Abstract: Longitudinal modelling of Alzheimer's disease progression is clinically useful only if it can describe not just the most likely next diagnosis, but how a patient may evolve over time and how reliable that forecast is.
Longitudinal modelling of Alzheimer's disease progression is clinically useful only if it can describe not just the most likely next diagnosis, but how a patient may evolve over time and how reliable that forecast is. Most deep learning approaches reduce this problem to single-step classification, treating cognitively normal, mild cognitive impairment, and dementia as flat categories while providing limited insight into how uncertainty accumulates across future visits.
arXiv:2607. 14190v1 Announce Type: new Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive and heterogeneous neurodegenerative disease in which predicting clinically meaningful milestones, such as assistive device use, remains challenging.
arXiv:2606. 27334v1 Announce Type: new Abstract: Digital twins have emerged as a promising paradigm for personalized healthcare, enabling modeling of individual behavior and health trajectories.
arXiv:2607. 11656v1 Announce Type: cross Abstract: Accurate diagnostic classification and disease-severity prediction for Alzheimer's disease are hampered by the incompleteness and heterogeneity of real-world clinical data.
In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits. Integrating these multimodal observations may improve diagnostic assessment, but naive fusion can degrade performance when MRI is noisy or intermittently unavailable.
arXiv:2606. 25185v1 Announce Type: new Abstract: Accurately predicting the spatiotemporal evolution of amyloid-$\beta$ and tau proteins at the individual level is critical for improving the diagnosis and treatment of Alzheimer's disease.
arXiv:2607. 07091v1 Announce Type: cross Abstract: In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits.
arXiv:2606. 07798v1 Announce Type: new Abstract: Alzheimer's disease is a progressive neurodegenerative disorder, and its progression varies substantially across patients.
arXiv:2606. 02228v1 Announce Type: cross Abstract: Predicting whether an individual with Alzheimer's disease will experience mild or severe disease progression is essential for personalized treatment.
Alzheimer's disease (AD) progression is often described through the amyloid-tau-neurodegeneration, or AT(N), cascade. However, most longitudinal models represent this cascade either as a fixed sequence of biomarkers or as a black-box forecasting task.